Despite their considerable size and resources, U.S. life sciences companies — like their peers in Europe and elsewhere — operate in a dynamic environment that presents numerous challenges to revenue and market share growth. Homi Kapadia, U.S. Life Sciences leader and vice chairman of Deloitte LLP, anticipates what is coming in 2015, including market consolidation, new models of innovation, growth in specialty therapeutic areas, R&D efficiency, and the data revolution. Read the full report: http://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/2015-life-sciences-outlook.html?id=us:2sm:3ss:outlook:awa:lshc:012315